Rick is a seasoned finance executive with deep experience in corporate finance, capital markets, M&A, and financial strategy. Over the course of his career, he has helped guide organizations through complex growth phases — ensuring strong governance, disciplined capital allocation, and long-term value creation.

A CPA with an MBA from the Ivey Business School at Western University, Rick brings expertise in IFRS and GAAP reporting, transaction structuring, and strategic financial planning. His work spans both operational leadership and capital markets engagement, bridging financial precision with forward-looking strategy.

At Artemis, Rick provides the financial stewardship required to scale innovation responsibly — supporting the company’s scientific ambition with clarity, rigor, and disciplined execution.

Alex Tropsha is one of the foundational architects of modern computational drug discovery, with a career defined by rigor, integrity, and an unwavering commitment to scientific validity.

A Professor at the University of North Carolina at Chapel Hill and Associate Dean at the UNC Eshelman School of Pharmacy, Alex has spent decades shaping how cheminformatics and quantitative structure–activity relationship (QSAR) modeling are applied to real-world drug discovery challenges. His work has helped establish the standards by which computational models are evaluated, interpreted, and trusted—bridging theoretical innovation with translational relevance.

Internationally recognized for his contributions to the field, Alex is the recipient of numerous prestigious honors, including the John Scott Award, Keppler Prize, and George Gamow Award, and is a Fellow of the American Institute for Medical and Biological Engineering. Beyond accolades, he is widely respected for advancing a principled approach to AI and modeling—one that prioritizes model validity, transparency, and scientific accountability.

At Artemis Discovery, Alex brings not only deep technical expertise, but a steady scientific compass. His guidance helps ensure that innovation remains grounded, claims remain defensible, and the platform evolves with the discipline and care required to turn computational insight into meaningful therapeutic impact.

Poul Sorensen is a physician-scientist and translational medicine leader whose work has helped bridge the gap between discovery science and real-world impact for patients, particularly in childhood cancer.

A Professor of Medicine at the University of British Columbia, Johal Endowed Chair in Childhood Cancer Research, and Director of the Academy of Translational Medicine at UBC, Poul has built his career at the interface of laboratory insight and clinical application. His leadership has advanced how promising discoveries are translated into meaningful therapeutic strategies, with a deep focus on improving outcomes for children and families facing cancer.

Recognized nationally and internationally for his contributions, Poul is a Fellow of the Royal Society of Canada and a recipient of numerous prestigious honors, including the Doctors of BC Terry Fox Medal, the Dr. Wei Memorial Prize in Cancer Research, and the Bloom Burton Award for innovative cancer research. These distinctions reflect a career defined by both scientific excellence and human-centered impact.

At Artemis Discovery, Poul brings a vital clinical and translational perspective—ensuring that scientific innovation remains connected to patient realities. His guidance helps shape a platform that not only accelerates discovery, but does so with purpose, responsibility, and a clear line of sight to meaningful clinical outcomes.